

IMPACT OF THE PROJECT

The specific expected results and impacts of the project activities, which will bring significant and direct benefits measurable within the monitored data are the following:

- 1 link on the institutional web providing information on the project activities and achievements,
- 2 clinical collaborations (1 international including academic hospital, 1 national private sector including hospital) via one member of the clinical group of the team,
- 2 analytical collaborations (1 international and 1 national including research institutions) via four members of the analytical group of the team,
- 1 top student, doctoral candidate, integrated into the analytical group of the team for developing expertise (human resources development),
- 1 ethical committee approval,
- 50 IBD patients included in the study,
- 50 samples taken from IBD patients included in the study,
- 3 innovative analytical methods for conducting IBD sample analyses of currently approved IBD medications, i.e., tofacitinib, upadacitinib, filgotinib
- 3 validated protocols as a guideline for conducting IBD samples analyses (TDM / pharmacokinetics) of currently approved JAKi such as tofacitinib, upadacitinib, filgotinib (from sampling, storage, preanalytical sample treatment and analysis parameters and conditions to validation parameters)
- 3 publications in scientific journals (devoting to analytical methodology, pilot clinical studies)
- 5 presentations (published abstracts) at international conferences and symposia (devoting to analytical methodology, and pilot clinical studies)